Literature DB >> 16962883

Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study.

Janaki Amin1, Matthew G Law, Mark Bartlett, John M Kaldor, Gregory J Dore.   

Abstract

BACKGROUND: Hepatitis B and hepatitis C virus infections are common causes of death related to liver disease. In this large study, we aimed to investigate all cause mortality of the viruses in a community-based setting.
METHODS: In the study population, 39,109 people had hepatitis B, 75,834 had hepatitis C, and 2604 had hepatitis B and hepatitis C co-infection, notified to the New South Wales state health department, Australia, between 1990 and 2002. Their data were probabilistically linked to the National Death Index. Standardised mortality ratios for all causes of death were calculated and adjusted for age, sex, and calendar year.
RESULTS: The number of deaths identified by the linkage were 1233 (3.2%) for hepatitis B, 4008 (5.3)% for hepatitis C, and 186 (7.1)% for hepatitis B and C co-infection. Raised risk of liver-related death (standardised mortality ratios 12.2, 95% CI 10.7-13.9; 16.8, 15.4-18.3, and 32.9, 23.1-46.7, for hepatitis B, hepatitis C, and hepatitis B and C co-infected patients, respectively) and drug-induced death (1.4, 1.0-2.0; 19.3, 18.1-20.5; and 24.7, 18.2-33.5, respectively) were detected. In people with hepatitis C, raised risk of dying from drug-related causes was significantly greater than from liver-related causes (p=0.012), with the greatest excess risk in women aged 15-24 years (56.9, 39.2-79.9).
INTERPRETATION: All groups had increased risk of liver-related death compared with the standard population, with the greatest excess in people diagnosed with hepatitis B and hepatitis C co-infection. Our data highlight that young people with hepatitis C and with co-infection face a higher mortality risk from continued drug use than from their infection, whereas the main cause of hepatitis B death was liver related.

Entities:  

Mesh:

Year:  2006        PMID: 16962883     DOI: 10.1016/S0140-6736(06)69374-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  59 in total

Review 1.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 2.  Hepatitis B virus epidemiology.

Authors:  Jennifer H MacLachlan; Benjamin C Cowie
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

Review 3.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

4.  Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study.

Authors:  Matteo Nicola Dario Di Minno; Pasquale Ambrosino; Antonio Riccardo Buonomo; Biagio Pinchera; Ilenia Calcaterra; Manuel Crispo; Riccardo Scotto; Francesco Borgia; Consalvo Mattia; Ivan Gentile
Journal:  Intern Emerg Med       Date:  2019-08-08       Impact factor: 3.397

Review 5.  Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.

Authors:  Simona Ruta; Costin Cernescu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

6.  Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems.

Authors:  Daniel Fuster; Debbie M Cheng; Emily K Quinn; David Nunes; Richard Saitz; Jeffrey H Samet; Judith I Tsui
Journal:  Addiction       Date:  2013-10-24       Impact factor: 6.526

Review 7.  Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.

Authors:  Nathan Ford; Catherine Kirby; Kasha Singh; Edward J Mills; Graham Cooke; Adeeba Kamarulzaman; Philipp duCros
Journal:  Bull World Health Organ       Date:  2012-02-03       Impact factor: 9.408

8.  All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type.

Authors:  Zachary S Wallace; Xiaoqing Fu; Tyler Harkness; John H Stone; Yuqing Zhang; Hyon Choi
Journal:  Rheumatology (Oxford)       Date:  2020-09-01       Impact factor: 7.580

Review 9.  Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.

Authors:  Ava John-Baptiste; Man Wah Yeung; Victoria Leung; Gabrielle van der Velde; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

10.  Hepatitis C virus infection and risk of cancer: a population-based cohort study.

Authors:  Lars Haukali Omland; Dora Körmendiné Farkas; Peter Jepsen; Niels Obel; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.